892154-56-2

Basic information

• Product Name: O,O'-BIS(2-AMINOETHYL)OCTADECAETHYLENE GLYCOL
• Synonyms: O,O'-Bis(2-aMinoethyl)octadecaethylene glycol >=95% (oligoMer purity);O,O′-Bis(2-aminoethyl)hexacosaethylene glycol
• CAS NO: 892154-56-2
• Molecular Formula: C40H84N2O19
• Molecular Weight: 0
• Product Categories: Chemical Biology;Chemical Synthesis;High Oligomer Purity PEG;PEGylation
• Mol File: 892154-56-2.mol
• Article Data: 53

Chemical Properties

• Boiling Point: 807.2°C at 760 mmHg
• Flash Point: 421.8°C
• Appearance: /
• Density: 1.097g/cm³
• Vapor Pressure: 4.22E-26mmHg at 25°C
• Refractive Index: 1.469
• CAS DataBase Reference: O,O'-BIS(2-AMINOETHYL)OCTADECAETHYLENE GLYCOL(CAS DataBase Reference)
• NIST Chemistry Reference: O,O'-BIS(2-AMINOETHYL)OCTADECAETHYLENE GLYCOL(892154-56-2)
• EPA Substance Registry System: O,O'-BIS(2-AMINOETHYL)OCTADECAETHYLENE GLYCOL(892154-56-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 892154-56-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C40H84N2O19/c41-1-3-43-5-7-45-9-11-47-13-15-49-17-19-51-21-23-53-25-27-55-29-31-57-33-35-59-37-39-61-40-38-60-36-34-58-32-30-56-28-26-54-24-22-52-20-18-50-16-14-48-12-10-46-8-6-44-4-2-42/h1-42H2

Upstream product

• 31255-11-5 1,8-diphthalimido-3,6-dioxaoctane 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 112-26-5 1,2-bis(2-chloroethoxy)ethane 
• 59559-06-7 1,8-diazido-3,6-dioxaoctane 
• 19249-03-7 triethylene glycol di-(p-toluenesulfonate) 
• 7664-41-7 ammonia 
• 55400-73-2 ((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) dimethanesulfonate 
• 4792-15-8 Pentaethylene glycol 
• 109789-39-1 pentaethylene glycol dimesylate 
• 182760-73-2 1,14-diazido-3,6,9,12-tetraoxatetradecane 
• 206265-98-7 O-(2-aminoethyl)-O′-[2-(boc-amino)ethyl]hexaethylene glycol 
• 57436-38-1 3,6,9,12,15,18,21-heptaoxatricosane-1,23-diyl bis(4-methylbenzenesulfonate) 
• 5117-19-1 octaethylene glycol 
• 37860-51-8 tetraethylene glycol di(p-toluenesulfonate) 

Downstream Products

• 1262210-10-5 C₅₄H₆₁N₇O₁₂ 
• 868599-73-9 9H-fluoren-9-ylmethyl N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamate hydrochloride 
• 79688-24-7 2-benzyl-1,7,10,13,16-pentaoxa-4,16-diaza-3,7,21-cycloheneicosanetrione 
• 89863-12-7 1,3,15,17-tetraaza-6,9,12,20,23,28,31-heptaoxabicyclo<15.8.8>tritriacontane-2,16-dithione 
• 75491-66-6 1,3,15,17-tetraaza-6,9,12,20,23,26-hexaoxacyclooctacosane-2,16-dithione 
• 811442-84-9 tert-butyl N-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate 
• 1644287-24-0 N,N'-bis-(3-oxo-3-(4-dimethylaminophenyl)propen-1-yl)-N,N'-dibenzyl-3,6-dioxaoctane-1,8-diamine 
• 1263166-93-3 [(1R,8S,9R)-bicyclo[6.1.0]non-4-yn-9-yl]methyl N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamate 
• 1314639-16-1 C₂₆H₃₇N₃O₉ 
• 1393600-24-2 C₂₇H₄₂N₄O₆S 

Relevant articles and documents

A CHIRAL RESOLUTION METHOD MIMICKING MAGNETIC BENEFICIATION AND THE MAGNETIC NANO-INHIBITORS FOR SELECTIVE ENRICHMENT

A core-shell nanocomposite is formed by co-assembly of an amphiphilic polymer and hydrophobically modified magnetic nanoparticles, with its core being a hydrophobically modified magnetic nanomaterial and its shell being the amphiphilic polymer, wherein hydrophilic segments in the amphiphilic polymer are located at an outermost layer of the shell. The above composite can be used as additives in the crystallization of conglomerates and obtain optically pure crystals of both enantiomers in a single process. The key thereof is that the composite is used to enrich molecules with the same configuration while inhibit the crystallization of the other enantiomer in a supersaturated solution of conglomerates, such that a non-magnetic crystal and a magnetic crystal (which are enantiomers of each other) are generated in a unit operation. Optically pure crystals of both enantiomers with over 90 ee % can be obtained by one-time crystallization, and the total yield can be as high as 40%.

Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Membrane fusion is a valid target for inhibition of HIV-1 replication. A 34-mer fragment peptide (C34), which is contained in the HIV-1 envelope protein gp41, has significant anti-HIV activity. Previously, a dimeric derivative of C34 linked by a disulfide bridge at its C-terminus was found to have more potent anti-HIV activity than the C34 peptide monomer. To date, several peptidomimetic small inhibitors have been reported, but most have lower potency than peptide derivatives related to C34. In the present study we applied this dimerization concept to these peptidomimetic small inhibitors and designed several bivalent peptidomimetic HIV-1 fusion inhibitors. The importance of the length of linkers crosslinking two peptidomimetic compounds was demonstrated and several potent bivalent inhibitors containing tethered peptidomimetics were produced.